005250.KS
Green Cross Holdings Corporation
KSC · Healthcare · Biotechnology · KR
KRW 9,850.00
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2487.4B | 2451.5B | 2204.9B | 2057.9B | 2079.6B |
| Cost of Revenue | 1842.6B | 1791.9B | 1584.5B | 1454.4B | 1381.2B |
| Gross Profit | 644.8B | 659.6B | 620.4B | 603.6B | 698.3B |
| Operating Expenses | |||||
| R&D Expense | 156.8B | 157.3B | 174.6B | 179.5B | 193.9B |
| SG&A Expense | 287.9B | 228.4B | 199.6B | 419.6B | 217.7B |
| General & Admin Expense | 109.0B | 51.1B | 53.2B | 54.1B | 56.0B |
| Selling & Marketing Expense | 178.9B | 177.3B | 146.5B | 146.7B | 161.7B |
| Other Expenses | 218.4B | 238.9B | 256.8B | 20.9B | 215.5B |
| Total Operating Expenses | 617.1B | 624.6B | 631.1B | 620.0B | 627.2B |
| Cost and Expenses | 2458.4B | 2415.2B | 2215.6B | 2074.4B | 2008.4B |
| Operating Income (EBIT) | 29.0B | 35.0B | (10.7B) | 2.6B | 72.0B |
| Non-Operating | |||||
| Interest Income | 5.4B | 5.5B | 7.0B | 6.5B | 5.6B |
| Interest Expense | 76.5B | 72.0B | 66.6B | 53.1B | 36.5B |
| Net Interest Income | (71.1B) | (66.5B) | (59.6B) | (46.6B) | (30.9B) |
| Other Non-Op Income/Expense | (164.7B) | (88.4B) | 53.2B | (83.7B) | (41.5B) |
| Non-Operating Income (excl Interest) | 105.0B | 17.9B | (119.8B) | 11.6B | (30.6B) |
| EBT (Pre-Tax Income) | (135.7B) | (53.4B) | 42.5B | (81.1B) | 30.4B |
| Income Tax Expense | 15.5B | (11.6B) | 53.6B | (9.5B) | (29.3B) |
| Bottom Line | |||||
| Net Income | (122.1B) | (69.5B) | 24.0B | (54.1B) | 32.8B |
| Earnings from Cont. Ops | (151.1B) | (41.8B) | (11.1B) | (71.6B) | 59.7B |
| Earnings from Discont. Ops | — | — | — | (1.2B) | (800.6M) |
| Bottom Line Net Income | (122.1B) | (69.5B) | 24.0B | (54.1B) | 32.8B |
| Per Share | |||||
| Basic EPS | (₩2,690) | (₩1,531) | ₩529 | (₩1,210) | ₩723 |
| Diluted EPS | (₩2,690) | (₩1,531) | ₩529 | (₩1,192) | ₩723 |
| Revenue Per Share | ₩54,786 | ₩54,033 | ₩48,563 | ₩45,997 | ₩45,803 |
| Shares | |||||
| Basic Shares Outstanding | 45.4M | 45.4M | 45.4M | 44.7M | 45.4M |
| Diluted Shares Outstanding | 45.4M | 45.4M | 45.4M | 45.4M | 45.4M |
| Profitability Metrics | |||||
| EBITDA | 157.9B | 142.2B | 212.8B | 66.8B | 180.2B |
| D&A | 107.7B | 107.2B | 103.7B | 94.8B | 78.7B |
| EBIT | 50.2B | 35.0B | 109.1B | (28.0B) | 101.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026